Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
R-Pharm US
NJ - Princeton
MEROPENEM (meropenem) by R-Pharm US is [ see microbiology () ]. Approved for bacterial meningitis caused by haemophilus influenzae, neisseria meningitidis andpenicillin-susceptible isolates of streptococcus pneumoniae, older. First approved in 2016.
Drug data last refreshed 1w ago
[ see Microbiology () ].
Worked on MEROPENEM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo